Market Overview

Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update


Conference call to take place November 7th, 2018, at 4:30 pm E.T.

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or "the
Company"), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today announced it will
host a conference call on Wednesday, November 7th, 2018, at
4:30 pm E.T. to discuss its financial results for the third quarter of
2018 in conjunction with the filing of its quarterly report on Form 10-Q.

Jed Latkin, Chief Executive Officer, and Erika Gibson, Director, Finance
and Administration, of Navidea Biopharmaceuticals will host the call and
provide an update on recent developments and clinical progress.
Management will be answering questions live immediately following the
financial earnings portion of the conference call.

Conference Call & Webcast Details

Investors and the public are invited to dial into the earnings call
through the conference call number below or participate via the audio
webcast on the company website,
Participants who would like to ask questions during the question and
answer session will be prompted by the moderator, who will provide

Event: Third Quarter 2018 Earnings and Business Update Conference Call
Date: Wednesday, November 7, 2018
Time: 4:30 pm (Eastern Time)
U.S. & Canada Dial-in: 877-407-0312
Conference ID: 13684819
Webcast Link:


The recorded conference call can be replayed and will be available for
90 days following the call, available on the investor relations page of
Navidea's corporate website at

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea's Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company's pipeline through global partnering and commercialization

For more information, please visit

Forward-Looking Statements

This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends affecting the financial condition of our business,
including our expectations regarding the Platinum-Montaur litigation and
related matters. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, including, among other
things: any future actions by Platinum-Montaur, general economic and
business conditions, both nationally and in our markets; our history of
losses and uncertainty of future profitability; the final outcome of the
CRG litigation in Texas; our ability to successfully complete research
and further development of our drug candidates; the timing, cost and
uncertainty of obtaining regulatory approvals of our drug candidates;
our ability to successfully commercialize our drug candidates; our
expectations and estimates concerning future financial performance,
financing plans and the impact of competition; our ability to raise
capital sufficient to fund our development and commercialization
programs; our ability to implement our growth strategy; anticipated
trends in our business; advances in technologies; our ability to comply
with the NYSE American continued listing standards; and other risk
factors set forth in this report and detailed in our most recent Annual
Report on Form 10-K and other SEC filings. You are urged to carefully
review and consider the disclosures found in our SEC filings, which are
available at or

Investors are urged to consider statements that include the words
"will," "may," "could," "should," "plan," "continue," "designed,"
"goal," "forecast," "future," "believe," "intend," "expect,"
"anticipate," "estimate," "project," and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial